Drugs that contain Aclidinium Bromide
1. Drug name - TUDORZA PRESSAIR
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE46417 | ASTRAZENECA | Quinuclidine derivatives and their use as muscarinic M3 receptor ligands |
Feb, 2025
(2 years from now) | |
| CN1373760A | ASTRAZENECA | M3 As Muscarinic Receptor Ligands Quinuclidine Derivatives And Their Use |
Jul, 2020
(2 years ago) | |
| CN100451018C | ASTRAZENECA | M3 As Muscarinic Receptor Ligands Quinuclidine Derivatives And Their Use |
Jul, 2020
(2 years ago) | |
| CN1824664A | ASTRAZENECA | M3 As Muscarinic Receptor Ligands Quinuclidine Derivatives And Their Use |
Jul, 2020
(2 years ago) | |
| CN1272334C | ASTRAZENECA | M3 As Muscarinic Receptor Ligands Quinuclidine Derivatives And Their Use |
Jul, 2020
(2 years ago) | |
| IN224375B | ASTRAZENECA | A Quaternary Quinuclidine Compound Of Formula (I) And Process For Preparing The Same |
Jul, 2020
(2 years ago) | |
| IN200200049P1 | ASTRAZENECA | Quinuclidine Derivatives And Their Use As Muscarinic M3 Receptor Ligands |
Jul, 2020
(2 years ago) | |
| EP1200431B1 | ASTRAZENECA | Quinuclidine Derivatives And Their Use As Muscarinic M3 Receptors Ligands |
Jul, 2025
(2 years from now) | |
| EP1200431A2 | ASTRAZENECA | Quinuclidine Derivatives And Their Use As Muscarinic M3 Receptors Ligands |
Jul, 2025
(2 years from now) | |
| EP1200431B3 | ASTRAZENECA | Quinuclidine Derivatives And Their Use As Muscarinic M3 Receptors Ligands |
Jul, 2025
(2 years from now) | |
| EP1200431BA | ASTRAZENECA | Quinuclidine Derivatives And Their Use As Muscarinic M3 Receptor Ligands |
Jul, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8051851 | ASTRAZENECA | Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler |
Apr, 2027
(4 years from now) | |
| US10085974 | ASTRAZENECA | Dosage and formulation |
Mar, 2029
(6 years from now) | |
| US11000517 | ASTRAZENECA | Dosage and formulation |
Mar, 2029
(6 years from now) | |
Treatment: Maintenance treatment of chronic obstructive pulmonary disease (copd)
Dosage: POWDER, METERED;INHALATION
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 0.4MG/INH | POWDER, METERED;INHALATION | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.